Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411333 · ClinicalTrials.gov registry record · Early Phase 1
Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy
A Early Phase 1 study, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
NCT00411333 is a Early Phase 1 study that has completed, run by National Eye Institute (NEI). The registered enrollment target is 100 participants.
The verdict
NCT00411333, a Early Phase 1 study, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The retinal vasculature changes dramatically in patients with diabetic retinopathy especially between non-proliferative and proliferative disease. The retinal vasculature can be imaged and quantified using special dyes. This study will test whether the pattern of the retinal vasculature changes in patients with different levels of diabetic retinopathy can be quantified using computerized image analysis. In addition, the study will evaluate whether new drugs to treat diabetic retinopathy will be able to reverse these vascular changes.
Interventions
- DRUG triamcinolone acetonide (Kenalog)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411333
The ClinicalTrials.gov registry entry for NCT00411333 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which triamcinolone acetonide (Kenalog) is the first listed.
NCT00411333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411333 about?
NCT00411333 is a clinical study titled "Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy". The retinal vasculature changes dramatically in patients with diabetic retinopathy especially between non-proliferative and proliferative disease. The retinal vasculature can be imaged and quantified using special dyes. This study will test whether the pattern of the retinal vasculature changes in p...
What is the current status of trial NCT00411333?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2006-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00411333?
The interventions under investigation include: triamcinolone acetonide (Kenalog) (DRUG).
Who is sponsoring clinical trial NCT00411333?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.